

## Breast Cancer Treatments

---

Reference Number: RDF2321-24

Date of Response: 01/03/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1<sup>st</sup> April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

*Dear Royal Devon University Healthcare NHS Foundation Trust,*

*Regarding breast cancer, I would greatly appreciate if you could answer the following question.*

*Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:*

Answer: Please see table below representing Royal Devon; latest 3 months available August to October 2023. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles. In these cases  $\leq 5$  is used to indicate that a figure between 1 and 5 is being suppressed.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

<b>Treatment</b>	<b>Count</b>
<i>Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)</i>	$\leq 5$
<i>Abemaciclib + Fulvestrant</i>	$\leq 5$
<i>Alpelisib + Fulvestrant</i>	$\leq 5$
<i>Anthracycline (e.g. doxorubicin or epirubicin) as a single agent</i>	$\leq 5$
<i>Atezolizumab + Nab-paclitaxel/Paclitaxel</i>	6
<i>Capecitabine as a single agent</i>	19
<i>Eribulin as a single agent or in combination</i>	8
<i>Everolimus + Exemestane</i>	Nil
<i>Fulvestrant as a single agent</i>	Nil
<i>Lapatinib</i>	Nil
<i>Neratinib</i>	Nil
<i>Parp Inhibitors (Olaparib/Talazoparib)</i>	Nil
<i>Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)</i>	42
<i>Palbociclib + Fulvestrant</i>	9

<i>Pembrolizumab</i>	Nil
<i>Platinum (e.g. carboplatin or cisplatin) as a single agent</i>	Nil
<i>Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)</i>	35
<i>Ribociclib + Fulvestrant</i>	9
<i>Sacituzumab Govitecan</i>	≤5
<i>Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent</i>	40
<i>Taxane and/or Anthracycline in combination</i>	Nil
<i>Trastuzumab as a single agent or in combination</i>	92
<i>Trastuzumab emtansine</i>	11
<i>Transtuzumab deruxtecan</i>	≤5
<i>Any other active systemic anti-cancer therapy</i>	162

Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

Answer: Please see table below representing Royal Devon current trials.

<b><i>Clinical trials for breast cancer</i></b>	<b><i>Count</i></b>
<i>ARTemis</i>	<5
<i>CONCEPT</i>	8
<i>DS8201-A-U301</i>	<5
<i>DS8201-A-U302</i>	<5
<i>EndoNET</i>	5
<i>FAST-Forward</i>	128
<i>IMPORT HIGH</i>	<5
<i>LORIS</i>	11
<i>MAMMO-50</i>	24
<i>APHINITY</i>	8
<i>OPTIMA</i>	71
<i>POETIC</i>	84
<i>POETIC-A</i>	6
<i>POSNOG</i>	14
<i>PRIMETIME</i>	78